Benign Prostatic Hyperplasia Prostate Treatment Market

Companies Dominating the Benign Prostatic Hyperplasia Prostate Treatment Landscape

Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Cardinal Health Inc.
NxThera, Inc.
Veru, Inc.
Teleflex Incorporated
Eli Lily & Company
Sanofi S.A.
GSK plc
Mylan N.V.
AbbVie Inc.

Browse Key Market Insights with Data Illustration:

Benign Prostatic Hyperplasia Prostate Treatment Market Size Forecasts 2036

In the News

Teleflex Incorporated announced the results of research studies regarding the efficacy and safety of UroLift systems. The system is developed for men diagnosed with benign prostatic hyperplasia (BPH) and median lobe obstruction.
Veru Inc. announced that it has received approval by the United States Food and Drug Administration (FDA) for its finasteride and tadalafil capsules, known as ENTADFI, which is used to treat urinary tract symptoms caused as a result of an enlarged prostate, commonly known as BPH.

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of benign prostatic hyperplasia prostate treatment is evaluated at USD 7.78 Billion.

The benign prostatic hyperplasia prostate treatment market size was over USD 7.4 Billion in 2023 and is set to exceed USD 15.21 Billion by the end of 2036, growing at over 5.7% CAGR during the forecast period i.e., between 2024-2036. Higher prevalence of benign prostatic hyperplasia (BPH), developing medical technology across the globe, increasing healthcare expenditure per capita, and spiking cases of urinary tract infection are estimated to majorly boost the market growth.

North America is projected to account for majority industry share by 2036, ascribed to rising geriatric population, an increasing unhealthy lifestyle, and a higher prevalence of benign prostatic hyperplasia.

Pfizer Inc., Cardinal Health Inc., NxThera, Inc., Veru, Inc., Teleflex Incorporated, Eli Lily & Company, Sanofi S.A., GSK plc, Mylan N.V., AbbVie Inc.

Benign Prostatic Hyperplasia Prostate Treatment Market - Top Companies and Manufacturers

Companies Dominating the Benign Prostatic Hyperplasia Prostate Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

Subscribe to Our Newsletters

Benign Prostatic Hyperplasia Prostate Treatment Market - Top Companies and Manufacturers

Companies Dominating the Benign Prostatic Hyperplasia Prostate Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is the benign prostatic hyperplasia prostate treatment market market?

What are the factors driving the benign prostatic hyperplasia prostate treatment market landscape?

Which region held the largest benign prostatic hyperplasia prostate treatment market industry share?

Who are the key players in the benign prostatic hyperplasia prostate treatment market sector?